drugset / Trial / NCT03764462

Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers

NCT03764462

Phase 1 Completed 52 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers

Timeline

Start
2018-12-14
Primary completion
2019-01-02
Completion
2019-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ISMIDENON Small molecule 45 mg Oral
Subject Raloxifene Other / unclassified 60 mg Oral

Indications